Stromedix

edit

Stromedix will focus initially on chronic indications but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer.

Milestones

edit

• Received $25M in Series B funding. (4/21/08)
  Posted 6/3/09 at 10:22pm
• Brad Maroni, Chief Medical Officer added.
  Posted 6/3/09 at 10:22pm
• Shelia Violette, Vice President, Research added.
  Posted 6/3/09 at 10:22pm
• Michael Gilman, Founder and CEO added.
  Posted 6/3/09 at 10:22pm
• Dan Lynch, Executive Chairman added.
  Posted 6/3/09 at 10:22pm

Videos

Screenshots

edit

Above: Homepage
Uploaded: 6/4/09

Sources

1. Capital Funding Report [edit]